245 related articles for article (PubMed ID: 33995658)
1. KAT6A, a novel regulator of β-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1.
Liu W; Zhan Z; Zhang M; Sun B; Shi Q; Luo F; Zhang M; Zhang W; Hou Y; Xiao X; Li Y; Feng H
Theranostics; 2021; 11(13):6278-6292. PubMed ID: 33995658
[No Abstract] [Full Text] [Related]
2. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
3. KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer.
Yu B; Luo F; Sun B; Liu W; Shi Q; Cheng SY; Chen C; Chen G; Li Y; Feng H
Adv Sci (Weinh); 2021 Oct; 8(20):e2100014. PubMed ID: 34392614
[TBL] [Abstract][Full Text] [Related]
4. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
5. Glycogen phosphorylase B promotes ovarian cancer progression via Wnt/β-catenin signaling and is regulated by miR-133a-3p.
Zhou Y; Jin Z; Wang C
Biomed Pharmacother; 2019 Dec; 120():109449. PubMed ID: 31627092
[TBL] [Abstract][Full Text] [Related]
6. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
7. Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding.
Lv D; Jia F; Hou Y; Sang Y; Alvarez AA; Zhang W; Gao WQ; Hu B; Cheng SY; Ge J; Li Y; Feng H
Cancer Res; 2017 Nov; 77(22):6190-6201. PubMed ID: 29021135
[TBL] [Abstract][Full Text] [Related]
8. KAT6B Is a Tumor Suppressor Histone H3 Lysine 23 Acetyltransferase Undergoing Genomic Loss in Small Cell Lung Cancer.
Simó-Riudalbas L; Pérez-Salvia M; Setien F; Villanueva A; Moutinho C; Martínez-Cardús A; Moran S; Berdasco M; Gomez A; Vidal E; Soler M; Heyn H; Vaquero A; de la Torre C; Barceló-Batllori S; Vidal A; Roz L; Pastorino U; Szakszon K; Borck G; Moura CS; Carneiro F; Zondervan I; Savola S; Iwakawa R; Kohno T; Yokota J; Esteller M
Cancer Res; 2015 Sep; 75(18):3936-45. PubMed ID: 26208904
[TBL] [Abstract][Full Text] [Related]
9. Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression.
Zhao W; Mo H; Liu R; Chen T; Yang N; Liu Z
Br J Cancer; 2022 Jul; 127(2):202-210. PubMed ID: 35332266
[TBL] [Abstract][Full Text] [Related]
10. Effect and mechanism of miR-217 on drug resistance, invasion and metastasis of ovarian cancer cells through a regulatory axis of CUL4B gene silencing/inhibited Wnt/β-catenin signaling pathway activation.
Liu HR; Zhao J
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):94-107. PubMed ID: 33506897
[TBL] [Abstract][Full Text] [Related]
11. Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis.
Choi HH; Guma S; Fang L; Phan L; Ivan C; Baggerly K; Sood A; Lee MH
Cell Cycle; 2015; 14(14):2265-73. PubMed ID: 25945542
[TBL] [Abstract][Full Text] [Related]
12. PHF19 promotes the proliferation, migration, and chemosensitivity of glioblastoma to doxorubicin through modulation of the SIAH1/β-catenin axis.
Deng Q; Hou J; Feng L; Lv A; Ke X; Liang H; Wang F; Zhang K; Chen K; Cui H
Cell Death Dis; 2018 Oct; 9(11):1049. PubMed ID: 30323224
[TBL] [Abstract][Full Text] [Related]
13. β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer.
Xu C; Liu F; Xiang G; Cao L; Wang S; Liu J; Meng Q; Xu D; Lv S; Jiao J; Niu Y
J Exp Clin Cancer Res; 2019 Jun; 38(1):238. PubMed ID: 31171012
[TBL] [Abstract][Full Text] [Related]
14. UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway.
Hu W; Li M; Chen Y; Gu X
J Ovarian Res; 2021 Sep; 14(1):121. PubMed ID: 34535173
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
16. The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology.
Wiesel-Motiuk N; Assaraf YG
Drug Resist Updat; 2020 Dec; 53():100729. PubMed ID: 33130515
[TBL] [Abstract][Full Text] [Related]
17. COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis.
Shao J; Teng Y; Padia R; Hong S; Noh H; Xie X; Mumm JS; Dong Z; Ding HF; Cowell J; Kim J; Han J; Huang S
Neoplasia; 2013 Sep; 15(9):1075-85. PubMed ID: 24027432
[TBL] [Abstract][Full Text] [Related]
18. Toosendanin reduces cisplatin resistance in ovarian cancer through modulating the miR-195/ERK/β-catenin pathway.
Wang G; Li L; Li Y; Zhang LH
Phytomedicine; 2023 Jan; 109():154571. PubMed ID: 36610147
[TBL] [Abstract][Full Text] [Related]
19. Circular RNA MTCL1 promotes advanced laryngeal squamous cell carcinoma progression by inhibiting C1QBP ubiquitin degradation and mediating beta-catenin activation.
Wang Z; Sun A; Yan A; Yao J; Huang H; Gao Z; Han T; Gu J; Li N; Wu H; Li K
Mol Cancer; 2022 Apr; 21(1):92. PubMed ID: 35366893
[TBL] [Abstract][Full Text] [Related]
20. MiR-30a-5p/CHD1 axis enhances cisplatin sensitivity of ovarian cancer cells via inactivating the Wnt/β-catenin pathway.
Wang X; Zhao H; Wang P; Zhang J; Li N; Liu Y; Zhang F; Yu Y
Anticancer Drugs; 2022 Nov; 33(10):989-998. PubMed ID: 36206129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
